solid-phase synthesis is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-04-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Acetylated peptide | N-terminal acetyl group blocks aminopeptidase attack |
| Residue count | 28 amino acids | Matches the N-terminus of prothymosin alpha |
| Molecular mass | About 3,108 Da | Value for the free, unmodified peptide |
| Isoelectric point | Approximately 4.2 | Acidic; net negative charge at neutral pH |
| Encoding gene | PTMA | Human gene for the precursor protein |
20世纪70年代，研究者从胸腺提取物中纯化出多种小肽，Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤，产量低且成分复杂。随着固相肽合成技术成熟，实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上，并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
The Alexander von Humboldt Fellowship to Germany (2003–2005) Visiting Scientist to the University of Pittsburgh, (2007–2008) The ANDI Bright Contest Award for the Best African Innovative Researcher, South Africa (2009) Young Scientist (representing Nigeria) at the "Summer Davos" Annual Meeting of New Champions, Tianjin, China (2010) CV Raman Senior Fellowship, India (2013) Fellow of the Nigerian Academy of Science (2017) Pioneer national president of the Nanomedicine Society of Nigeria Recipient of various national and international grants and a reviewer to several national and international journals.
In December 1940, Franz Simon at Oxford wrote his Estimate of the size of an actual separation plant." Simon proposed gaseous diffusion as the best method for uranium isotope separation. On 28 March 1941, Emilio Segré and Glen Seaborg reported on the "strong indications that 239Pu undergoes fission with slow neutrons." This meant chemical separation was an alternative to uranium isotope separation. Instead, a nuclear reactor fueled with ordinary uranium could produce a plutonium isotope as a nuclear explosive substitute for 235U. In May, they demonstrated the cross section of plutonium was 1.7 times that of U235. When plutonium's cross section for fast fission was measured to be ten times that of U238, plutonium became a viable option for a bomb. In October 1941, MAUD released its final report to the U.S. Government. The report stated, "We have now reached the conclusion that it will be possible to make an effective uranium bomb...The material for the first bomb could be ready by the end of 1943..." In November 1941, John Dunning and Eugene T. Booth were able to demonstrate the enrichment of uranium through gaseous barrier diffusion. On 27 November, Bush delivered to third National Academy of Sciences report to Roosevelt. The report, amongst other things, called for parallel development of all isotope-separation systems. On 6 December, Bush and Conant reorganized the Uranium Committee's tasks, with Harold Urey developing gaseous diffusion, Lawrence developing electromagnetic separation, Eger V.
=== Phase 3 === Altropane (123-I Altropane; [123I]-E-IACFT; NAV-5001; O-587) – dopamine reuptake inhibitor (DRI) and single-photon emission-computed tomography (SPECT) enhancer [3] Apomorphine (Aporon) – non-selective dopamine receptor agonist and other actions [4] Apomorphine sublingual film (APL-130277; Kynmobi) – non-selective dopamine receptor agonist and other actions [5] Bemdaneprocel (BRT-DA01; DA-01; MSK-DA01; pluripotent stem cell derived dopaminergic neurons) – dopaminergic cell replacement [6] Buntanetap ((+)-(3aR)-phenserine; (+)-phenserine; ANVS-401; ANVS-405; ANVS402; posiphen) – various actions [7] 18F-LBT-999 ([18F]-LBT-999; LBT-999) – dopamine reuptake inhibitor (DRI) and positron-emission tomography (PET) enhancer – diagnosis [8] Nabilone controlled release (Nabilone FDT) – cannabinoid CB1 and CB2 receptor agonist [9] Pramipexole/rasagiline (P2B-001; rasagiline/pramipexole) – combination of pramipexole (dopamine D2-like receptor agonist) and rasagiline (MAO-B inhibitor) [10] Remlifanserin (ACP-204) – serotonin 5-HT2A receptor antagonist – Parkinson's disease psychosis [11] Solengepras (CVN-424) – G protein-coupled receptor 6 (GPR6) inhibitor [12] Tavapadon (CVL-751; PF-6649751; PF-06649751) – dopamine D1 and D5 receptor agonist [13]
Some prohormones contain structures other than inactive peptide hormones for the purpose of keeping hormone expression suppressed. For example, proinsulin contains an extra non-hormonal chain called C-peptide that binds two insulin peptide chains together, designed to keep both chains inactive by binding to their ends, specifically, their C-domain junctions, which have been proposed to be their site of binding to hormone-expression receptors in the cell. Despite the restrictions it enables, the C-peptide folds the proinsulin chains to make their junction ends accessible to be cleaved by prohormone convertases later, making the folding of the proinsulin chain containing C-peptide essential for the proper cleavage of proinsulin to successfully produce insulin.
Erythromycin 12 hydroxylase (EC 1.14.13.154, EryK) is an enzyme with systematic name erythromycin-D,NADPH:oxygen oxidoreductase (12-hydroxylating) . This enzyme catalyses the following chemical reaction
Sources: en.wikipedia.org
== Function == Peritenon provides vascular supply for Achilles tendon along with vessels from musculotendinous junction proximally, the periosteum distally. There is a relatively avascular zone located 2–6 cm proximal to its insertion that is named "watershed area of the tendo Achilles". The watershed area's blood supply is mainly from the peritenon, specifically vessels in the mesotenon anteriorly.
Under conditions of low oxygen concentration in the bloodstream, such as exercise, stress, altitude, or dehydration, HbS polymerisation forms fibrous precipitates within the red blood cell. In people homozygous for the sickle cell mutation, the presence of long-chain polymers of HbS distort the shape of the red blood cell from a smooth, doughnut-like shape to the sickle shape, making it fragile and susceptible to blocking or breaking within capillaries. In people heterozygous for HbS (carriers of sickle cell disease), the polymerisation problems are minor because the normal allele can produce half of the haemoglobin. Sickle cell carriers have symptoms only if they are deprived of oxygen (for example, at altitude) or while severely dehydrated.
Ross (1971), historian and professor at University of Southern California, 2018 Pulitzer Prize for History finalist Roy Rosenzweig (1971), historian and director of the Center for History and New Media at George Mason University Scott Atran (1972), anthropologist; director at Centre National de la Recherche Scientifique and presidential scholar at John Jay College of Criminal Justice Joel Black (1972), literature and film scholar Michael Gerrard (1972), professor at Columbia Law School Jerome Groopman (1972), Harvard Medical School professor and medical writer for The New Yorker Robert Hymes (1972), professor of Chinese history at Columbia University, winner of two Joseph Levenson Book Prizes George Klosko (1972), professor of philosophy at the University of Virginia Mark J. Roe (1972), professor at Harvard Law School John Servos (1972), professor and historian of science; president of the History of Science Society David Stern (1972), professor of Hebrew literature at Harvard University Tom R. Tyler (1972), professor of psychology at Yale Law School Harold Aram Veeser (1972), professor at City College of New York, known for contribution to new historicism Sean Wilentz (1972), historian and winner of the Bancroft Prize; chair of American Studies at Princeton University Angelo Falcón (1973), political scientist, president and founder of the National Institute for Latino Policy Steven Messner (1973), sociologist, professor of the University at Albany, SUNY, former president of the American Society of Criminology William C.
A chronic wound is a wound that does not progress through the normal stages of wound healing—hemostasis, inflammation, proliferation, and remodeling—in a predictable and timely manner. Typically, wounds that do not heal within three months are classified as chronic. Chronic wounds may remain in the inflammatory phase due to factors like infection or bacterial burden, ischaemia, presence of necrotic tissue, improper moisture balance of wound site, or underlying diseases such as diabetes mellitus. In acute wounds, a regulated balance of pro-inflammatory cytokines (signalling molecules) and proteases (enzymes) prevent the degradation of the extracellular matrix (ECM) and collagen to ensure proper wound healing. In chronic wounds, there is excessive levels of inflammatory cytokines and proteases, leading to excessive degradation of the ECM and collagen. This disrupts tissue repair and impedes recovery, keeping the wound in a non-healing state. Chronic wounds may take years to heal or, in some cases, may never heal, causing significant physical and emotional stress for patients and placing a financial burden on healthcare systems. Acute and chronic wounds are part of a spectrum, with chronic wounds requiring prolonged and complex care compared to acute wounds.
Sources: en.wikipedia.org
Thymosin fraction 5 is a mixture of many peptides obtained from thymus tissue, while thymosin alpha 1 is a single defined 28-residue molecule. The two names appear together in older literature because the purified peptide was first obtained from that mixture.
The precursor, prothymosin alpha, is encoded by the PTMA gene in humans. The 28-residue peptide corresponds to the N-terminal segment released from that larger protein.
It is produced as a fragment of prothymosin alpha and is present in many tissues. Circulating concentrations are low, which makes routine measurement difficult.
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.